A single arm, prospective, open-label, pilot study to assess effects of the switch from sirolimus to everolimus in stable maintenance renal transplant patients receiving a calcineurin inhibitor free regimen.
Phase of Trial: Phase IV
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 01 Nov 2011 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 14 Nov 2005 New trial record.